Search results
Added:
2 months ago
Source:
Radcliffe Cardiology
While social determinants of health (SDOH) are known to influence outcomes in acquired cardiovascular diseases, their impact on conditions with a strong genetic basis, such as hypertrophic cardiomyopathy (HCM), has been less clear.² A new study using data from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) suggests that area-based social factors are independently associated with adverse…
View more
Increased Systolic Blood Pressure Variability Over Time Linked to Higher Risk of CVD, CKD, and Death
Added:
9 months ago
Source:
Radcliffe CVRM
News
Added:
7 months ago
Source:
Radcliffe Cardiology
Treatment with volenrelaxin, a long-acting human relaxin analogue, was associated with worsening congestion in patients with recently decompensated heart failure with preserved ejection fraction (HFpEF), leading to the early termination of the phase 2 RELAXIN-LA trial.¹ Despite this, the lowest dose of the drug did show an improvement in the study's primary endpoint.Relaxin is a peptide hormone…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Observational studies have long suggested that women who experience hypertensive disorders of pregnancy (HDP) face a greater risk of cardiovascular disease (CVD) later in life. A new genetic epidemiological study has explored whether this association is causal, using Mendelian randomization (MR) to investigate the genetic underpinnings of this risk. The findings suggest a genetic predisposition…
View more
Added:
9 months ago
Source:
ESC Congress 2025 Scientific Programme
Ten hot line sessions have been announced for ESC Congress 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Hot Line 1Friday 29th August, 11:00am – 12:00pm (CEST)POTCAST – a Randomized Controlled Trial of Arrhythmia prevention using targeted plasma potassium levels in ICD Patients – Presented by Christian…
View more
Added:
9 months ago
Source:
ESC Congress 2025 Scientific Programme
ESC Congress 2025 has released twenty-eight late-breaking trials and science sessions to be presented in August 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Late-Breaking Clinical Science: Inflammation and Immune Biomarkers in Cardiovascular Risk PredictionFriday 29th August, 08:15am – 09:45am (CEST…
View more
Added:
7 months ago
Source:
HFSA 2025 Scientific Programme
HSFA Annual Scientific Meeting 2025 has released its late-breaking clinical research sessions which are to be presented in September 2025.The meeting is set to take place from the 26th to 29th September 2025 at Minneapolis Convention Center in Minnesota, US.Access the full programme here.Late Breaking Clinical Research 1: Devices and CardiomyopathiesSunday 28th September, 09:00am – 10:30am (CDT…
View more
Added:
1 year ago
Source:
ESC Congress
The European Society of Cardiology has revealed 12 Hot-Line trial sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30thAugust to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View from the…
View more
Added:
1 year ago
Source:
ACC 2025
Watch our comprehensive coverage of ACC 2025's top trials here.The American College of Cardiology has announced the late-breaking trial and featured clinical research presentations for its 74th annual scientific sessions.ACC 2025 will be held from the 29th to 31st March at McCormick Place in Chicago.View the full programme here.Late-Breaking Clinical Trials I (Session 102)Saturday 29th March, 09…
View more
Added:
1 month ago
Source:
Radcliffe Cardiology
The routine use of beta-blockers following myocardial infarction (MI) in patients with a preserved ejection fraction has been a topic of clinical uncertainty. A new large-scale, individual-patient data meta-analysis from the Beta-Blocker Trialists’ Collaboration Study Group, combining five major trials, has found no significant benefit for this patient population.¹MethodologyThis meta-analysis…
View more